Noble, Sian M. http://orcid.org/0000-0002-8011-0722
Garfield, Kirsty
Lane, J. Athene
Metcalfe, Chris
Davis, Michael
Walsh, Eleanor I.
Martin, Richard M.
Turner, Emma L.
Peters, Tim J.
Thorn, Joanna C.
Mason, Malcolm
Bollina, Prasad
Catto, James W. F.
Doherty, Alan
Gnanapragasam, Vincent
Hughes, Owen
Kockelbergh, Roger
Kynaston, Howard
Paul, Alan
Paez, Edgar
Rosario, Derek J.
Rowe, Edward
Oxley, Jon
Staffurth, John
Neal, David E.
Hamdy, Freddie C.
Donovan, Jenny L.
Funding for this research was provided by:
DH | NIHR | Health Technology Assessment Programme (96/20/06, 96/20/99, 96/20/06, 96/20/99, 96/20/06, 96/20/99, 96/20/06, 96/20/99, 96/20/06, 96/20/99, 96/20/06, 96/20/99, 96/20/06, 96/20/99)
Cancer Research UK (C11043/A4286, C18281/A8145, C18281/A11326, C18281/A15064, and C18281/A24432)
Article History
Received: 7 November 2019
Revised: 8 June 2020
Accepted: 25 June 2020
First Online: 16 July 2020
Ethics approval and consent to participate
: The UK’s East Midlands (formerly Trent) Multicenter Research Ethics Committee (reference number 01/4/025) gave ethical approval. The study was performed in accordance with the Declaration of Helsinki. All participants provided their informed consent before participating in the study.
: Not applicable.
: On request to the ProtecT study, we will provide a patient deidentified set of EQ-5D-3L scores from Baseline (Biopsy) onwards, mortality information and annual costs at the Outpatient, Inpatient, GP and medication level, for prostate cancer-related research as per informed consent for researchers within the EU.
: S.M.N., K.G., J.A.L., C.M., M.D., E.I.W., T.J.P., F.C.H., D.E.N. and J.L.D. had financial support from NIHR HTA and J.C.T., R.M.M. and E.L.T. from CRUK for the submitted work; M.M. reports personal fees from Janssen Endocyte and Clovis’ and scientific advisor to Ellipsis Pharma and to Oncotherics, outside the submitted work. All other authors declare no conflict of interest.
: The ProtecT trial was funded by project grants 96/20/06 and 96/20/99 from the UK National Institute for Health Research, Health Technology Assessment Programme. R.M.M. is supported in part by the National Institute for Health Research Bristol Biomedical Research Centre and by a Cancer Research UK (C18281/A19169) programme grant (the Integrative Cancer Epidemiology Programme). R.M.M., E.L.T., J.C.T. and E.I.W. are supported in part through the CAP trial, which is funded by Cancer Research UK and the UK Department of Health (C11043/A4286, C18281/A8145, C18281/A11326, C18281/A15064, and C18281/A24432). J.A.L., C.M. and K.G. are supported in part by the Bristol Randomised Trials Collaboration (BRTC), a UKCRC registered clinical trials unit which, as part of the Bristol Trials Centre, is in receipt of National Institute for Health Research CTU support funding.